Mode
Text Size
Log in / Sign up
Phase 4 N=100 Randomized Single-blind Treatment

Psoas Compartment Block Versus Periarticular Local Anesthetic for Total Hip Arthroplasty

Osteoarthritis · Arthroplasty

Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Apr 2018
Primary outcome: Primary: Pain Score at 3 Hours — 4.0; 2.9 units on a scale — p=0.036

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Ropivacaine with NaCl (Drug); Epinephrine (Drug); Morphine (Drug); Ketorolac Tromethamine (Drug); Ropivacaine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Corewell Health East
Primary completion
May 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Score at 3 Hours
4.0; 2.9 0.036 sig
SECONDARY
Pain Score at 3-24 Hours
1.9; 1.3 0.204
SECONDARY
Pain Score at 24-48 Hours
1.9; 1.7 1.0
SECONDARY
Opioid Usage In-hospital at 24 Hours
19.5; 16.7 0.741
SECONDARY
Opioid Usage In-hospital at 48 Hours
22.3; 20.8 1.0

Summary

The primary objective of this study is to examine whether there is a difference in the level of resting pain following total hip arthroplasty with an anterior approach with use of a psoas compartment block versus a local periarticular anesthetic infiltration

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing unilateral primary total hip arthroplasty by Dr. James Verner at Beaumont Hospital Royal Oak
  • Have a diagnosis of primary osteoarthritis (i.e. degenerative joint disease)
  • Surgical approach is anterior

Exclusion Criteria

  • Minors (age less than 18 years)
  • Pregnant (surgically sterile, post-menopausal, or negative blood test)
  • Previous ipsilateral hip surgery
  • Lumbar instrumentation
  • Acute trauma
  • Rheumatoid arthritis
  • Avascular necrosis
  • Hip dysplasia
  • Known sensitivity, allergy, or contraindication to anesthetics being used in the study
  • Narcotic sensitivity
  • History of over 6 months of opioid dependency prior to surgery (excluding tramadol)
  • Peripheral neuropathy
  • Mental/cognitive impairment that would interfere with the patient's self-assessments of function, pain, or quality of life
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02658149). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search